Corbevax gets emergency use nod for 12-18 age group

Contact Counsellor

Last Updated22/02/2022

Hyderabad-based Biological E’s Covid-19 vaccine Corbevax was given emergency use nod for the 12-18 age group by the Drugs Controller General of India (DCGI)
Currently Bharat Biotech’s Covaxin is only administered in India for this age group

It is India’s first indigenously developed Receptor Binding Domain (RBD) protein subunit vaccine against Covid-19.
It received emergency use authorization for the adult population in December last year.
It is built on the traditional subunit vaccine platform.
Instead of using the whole virus, the platform triggers an immune response by using its fragments, like the spike protein.
The sub-unit vaccine contains harmless S-protein.
Once the human immune system recognises the S-protein, it produces antibodies as white blood cells that fight the infection.

It has been developed by the company Bharat Biotech India (BBIL) in collaboration with ICMR’s National Institute of Virology (NIV).
It is an “inactivated” vaccine
It is made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate.
Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against the dead virus

Covishield:
It is a Recombinant Chimpanzee Adenovirus vector vaccine (Covishield), encoding the SARS-CoV-2 Spike (S) glycoprotein
It is a ""non-replicating viral vector""
It makes use of another weakened and genetically modified virus, it is based on viral vector based technology
It carries the code to make the spike protein that is the spike on the surface of the virus.
It is supposed that the immune system of the body will recognise this protein as a threat and work on building antibodies against it.
It is being developed by AstraZeneca and the University of Oxford.
It is developed and manufactured by the Serum Institute of India(SII) through a licence from AstraZeneca and Oxford.
Sputnik V: it is created using different Human Adenoviruses
It is a two-dose vaccine.
Its efficacy is 91%
Sputnik V vaccine is manufactured using vector based platform
It is developed by Gamleya Research Institute of Epidemiology and Microbiology in Moscow.
It is distributed in India by Dr Reddy’s laboratory.
ZyCov – D: it is the second indigenous vaccine next to COVAXIN
It is developed on plasmid DNA i.e a piece of DNA of the weakened or killed virus is being used
When this DNA piece is injected into the body, the human immune systems learn to respond against the virus.
The plasmid is produced using E Coli cells.
Its unique feature is that it is needle less vaccine
Its efficacy is 66.6%
It is developed by the Indian Pharmaceutical company Cadila Healthcare